Table 2 Grade 2 or greater toxicities observed in ≥1 patient

From: Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

 

Nivolumab–ipilimumab (n = 10)

n (%)

Nivolumab–ipilimumab plus CBM588 (n = 19)

n (%)

Grade 2

Grade 3

Grade 4

Grade 2

Grade 3

Grade 4

Overall

2 (20)

5 (50)

0 (0)

6 (32)

9 (47)

1 (5)

Neutrophil count decreased

1 (10)

    

1 (5)

Fatigue

 

1 (10)

 

3 (19)

1 (5)

 

Glucose intolerance

 

1 (10)

 

1 (5)

1 (5)

 

Diarrhea

 

1 (10)

 

1 (5)

1 (5)

 

Adrenal insufficiency

   

3 (19)

1 (5)

 

Rash maculopapular

   

2 (11)

1 (5)

 

Acute kidney injury

 

1 (10)

 

1 (5)

1 (5)

 

Abdominal pain

    

1 (5)

 

Alkaline phosphatase increase

    

1 (5)

 

Acidosis

    

1 (5)

 

Chest wall pain

    

1 (5)

 

Pancreatitis

    

1 (5)

 

Transaminitis

 

1 (10)

 

5 (26)

1 (5)

 

Pruritus

 

1 (10)

    

Dehydration

 

1 (10)

    

Hypothyroidism

1 (10)

  

3 (19)

  

Hyperthyroidism

   

3 (19)

  

Arthralgia or myalgia

   

4 (22)

  

Weight gain

   

2 (11)

  
Back to article page